86 related articles for article (PubMed ID: 9113)
1. [Changes in drug elimination under the influence of perazine therapy (author's transl)].
Petruch F; Schüppel R; Breyer U
Arzneimittelforschung; 1976; 26(6):1154-5. PubMed ID: 9113
[TBL] [Abstract][Full Text] [Related]
2. [Relationship between perazine serum concentration and clinical results in long-term treated schizophrenic outpatients (author's transl)].
Pietzcker A; Müller-Oerlinghausen B; Schley J; Chaskel H; Poppenberg A; Urban R
Arzneimittelforschung; 1978; 28(8):1302-3. PubMed ID: 37850
[TBL] [Abstract][Full Text] [Related]
3. Prediction and evaluation criteria in perazine therapy of acute schizophrenics. Pharmacokinetic data.
Breyer-Pfaff U; Brinkschulte M; Rein W; Schied HW; Straube E
Pharmacopsychiatria; 1983 Sep; 16(5):160-5. PubMed ID: 6140695
[TBL] [Abstract][Full Text] [Related]
4. Proceedings: Effect of chronic treatment with perazine (Taxilan-R) on the pharmacokinetic behaviour of phenazone in man.
Schüppel RV; Petruch F
Naunyn Schmiedebergs Arch Pharmacol; 1975; 287 Suppl():R90. PubMed ID: 238154
[No Abstract] [Full Text] [Related]
5. [Effect of metronidazole on phenazone metabolism].
Staiger C; Wang NS; de Vries J; Weber E
Arzneimittelforschung; 1984; 34(1):89-91. PubMed ID: 6538427
[TBL] [Abstract][Full Text] [Related]
6. Distribution interactions between perazine and antidepressant drugs. In vivo studies.
Wójcikowski J; Daniel WA
Pol J Pharmacol; 2000; 52(6):449-57. PubMed ID: 11334238
[TBL] [Abstract][Full Text] [Related]
7. Phenazone as a marker of liver-metabolic function in patients with acute leukemia.
Wiela-Hojenska A; Orzechowska-Juzwenko K; Usnarska-Zubkiewicz L; Kotlarek-Haus S; Hurkacz M
Int J Clin Pharmacol Ther; 1999 May; 37(5):234-7. PubMed ID: 10363621
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of phenothiazine neuroleptics after chronic coadministration of carbamazepine.
Daniel WA; Syrek M; Haduch A; Wójcikowski J
Pol J Pharmacol; 1998; 50(6):431-42. PubMed ID: 10385926
[TBL] [Abstract][Full Text] [Related]
9. The metabolism of the piperazine-type phenothiazine neuroleptic perazine by the human cytochrome P-450 isoenzymes.
Wójcikowski J; Pichard-Garcia L; Maurel P; Daniel WA
Eur Neuropsychopharmacol; 2004 May; 14(3):199-208. PubMed ID: 15056479
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral administration.
Eichelbaum M; Ochs HR; Roberts G; Somogyi A
Arzneimittelforschung; 1982; 32(5):575-8. PubMed ID: 7201837
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological studies on perazine and its primary metabolites.
Brand U; Menge HG; Neumann BW; Stille G
Pharmacopsychiatry; 1989 Nov; 22(6):255-7. PubMed ID: 2575764
[TBL] [Abstract][Full Text] [Related]
12. [Specific binding of perazine, a piperazine side-chain phenothiazine drug, to a serum protein (author's transl)].
Schley J; Nündel M; Riedel E; Müller-Oerlinghausen B
Arzneimittelforschung; 1979; 29(1):106-8. PubMed ID: 36101
[TBL] [Abstract][Full Text] [Related]
13. [An attempt at assessment of biotransformation activity in calves' liver on the basis of the rate of antipyrine elimination from saliva].
Janus K; Baranow-Baranowski S; Jakubowska D
Pol Arch Weter; 1991; 31(3-4):65-71. PubMed ID: 1842615
[TBL] [Abstract][Full Text] [Related]
14. Phenazone pharmacokinetics as an index of hepatic metabolic efficiency.
Wiela A; Orzechowska-Juzwenko K; Kotlarek-Haus S; Plamieniak B; Wolowiec D
Int J Clin Pharmacol Ther Toxicol; 1988 Nov; 26(11):562-5. PubMed ID: 3243660
[TBL] [Abstract][Full Text] [Related]
15. Outcome and risks of ultra-long-term treatment with an oral neuroleptic drug. Relationship between perazine serum levels and clinical variables in schizophrenic outpatients.
Pietzcker A; Poppenberg A; Schley J; Müller-Oerlinghausen B
Arch Psychiatr Nervenkr (1970); 1981; 229(4):315-29. PubMed ID: 6111989
[TBL] [Abstract][Full Text] [Related]
16. [Thin-layer chromatographic determination of plasma levels of tricyclic psychopharmacological drugs: first results on their relationship to the clinical activity of neuroleptics (author's transl)].
Breyer U; Petruch F; Gaertner HJ; Pflug B
Arzneimittelforschung; 1976; 26(6):1153. PubMed ID: 989405
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine.
Bender S; Olbrich HM; Fischer W; Hornstein C; Schoene W; Falkai P; Haarmann C; Berger M; Gastpar M;
Pharmacopsychiatry; 2003; 36(2):61-9. PubMed ID: 12734763
[TBL] [Abstract][Full Text] [Related]
18. Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man.
Teunissen MW; van der Veen EA; Doodeman PJ; Breimer DD
Eur J Clin Pharmacol; 1984; 27(1):99-103. PubMed ID: 6489432
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of the capacity of the liver for phenazone biotransformation in patients with uremia on peritoneal dialysis].
Grzegorzewska A; Lowicki Z; Chmara E; Mrozikiewicz A; Baczyk K
Pol Tyg Lek; 1990 Apr 16-30; 45(16-18):339-41. PubMed ID: 2235722
[TBL] [Abstract][Full Text] [Related]
20. Effect of schistosomiasis infection on the clearance of phenazone in mice.
Metwally AA; Janku I; Kemper F; Khayyal MT; Ebeid FA; Botros SS
Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):206-9. PubMed ID: 2110459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
